Lipid Metabolism, Inborn Errors: Clinical Trials

1,148 trials for Lipid Metabolism, Inborn Errors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

605 completed, 152 recruiting, 136 unknown, 82 terminated. 222 Phase 2, 194 Phase 1, 186 Phase 3, 148 Not applicable, 47 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2222Completed 131, Terminated 27, Active not recruiting 15, Unknown 15, Recruiting 13, Not yet recruiting 10, Withdrawn 9, Suspended 2
Phase 1194Completed 126, Recruiting 16, Terminated 16, Active not recruiting 14, Not yet recruiting 8, Unknown 6, Withdrawn 6, Suspended 2
Phase 3186Completed 124, Recruiting 17, Terminated 17, Active not recruiting 9, Not yet recruiting 6, Unknown 6, Withdrawn 6, Enrolling by invitation 1
Not applicable148Completed 73, Unknown 28, Recruiting 20, Active not recruiting 8, Terminated 8, Not yet recruiting 5, Enrolling by invitation 3, Withdrawn 3
Phase 447Completed 33, Withdrawn 5, Unknown 4, Terminated 3, Recruiting 2
Early Phase 115Recruiting 5, Unknown 4, Completed 3, Active not recruiting 2, Not yet recruiting 1

Follow Lipid Metabolism, Inborn Errors: new trials by email Literature Review of Lipid Metabolism, Inborn Errors trials Research Report on Lipid Metabolism, Inborn Errors

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02
A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
Gaucher Disease
Not yet recruitingTakeda602027-01-312026-10-01
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
AZ-3102 - Gaucher Disease Type 3
Phase 2Not yet recruitingAzafaros B.V.202027-01-252026-11-12
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I
Phase 1Not yet recruitingTippi Mackenzie52027-01-012026-08-31
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
Hypercholesterolaemia, Familial Hypercholesterolaemia
Not yet recruitingFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)25002027-01-012026-11-03
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
GD2, PSMA and CD276 CAR-T cells - Neuroblastoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-10-30
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease
Phase 2Not yet recruitingPolaryx Therapeutics, Inc.242026-12-012026-07-31
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Lucerastat - Fabry Disease
Phase 3RecruitingIdorsia Pharmaceuticals Ltd.162026-12-012026-11-03
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3
Cascade Screening - Familial Hypercholesterolemia
Not applicableNot yet recruitingNorthwestern University1102026-11-152026-11-05
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 1 / Phase 2Not yet recruitingEditas Medicine, Inc.562026-11-012026-10-26
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
PLX-200, Placebo - Juvenile Neuronal Ceroid Lipofuscinosis
Phase 3WithdrawnPolaryx Therapeutics, Inc.2026-11-012026-08-19
Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)
Decision tree for initiating treatment - Fabry Disease
Not applicableNot yet recruitingUniversity Hospital, Bordeaux602026-11-012026-10-14
Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome
Elamipretide - Barth Syndrome
Phase 1Not yet recruitingStealth BioTherapeutics Inc.62026-11-012026-11-10
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP
Cascade testing, Standard of Care - Familial Hypercholesterolemia
Not applicableNot yet recruitingMayo Clinic4802026-10-202026-09-18
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Zodasiran - Homozygous Familial Hypercholesterolemia
Phase 3RecruitingArrowhead Pharmaceuticals102026-10-012026-10-26
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial
Not yet recruitingAssistance Publique - Hôpitaux de Paris14162026-10-012026-09-02
Nutritional Status of Gaucher Disease Patients
Gaucher Disease
Not yet recruitingAssiut University842026-09-262026-09-28

Showing 20 of 1148. Sign in to see all of them.

Narrower conditions

Fabry Disease (243)  ·  Hyperlipoproteinemia Type II (227)  ·  Gaucher Disease (176)  ·  Hypercholesterolemia (70)  ·  Homozygous Familial Hypercholesterolemia (67)  ·  Lecithin Cholesterol Acyltransferase Deficiency (62)  ·  Lysosomal Storage Diseases (62)  ·  Leukodystrophy, Metachromatic (49)  ·  Neuronal Ceroid-Lipofuscinoses (49)  ·  Cardiovascular Diseases (38)  ·  Metabolism, Inborn Errors (37)  ·  Niemann-Pick Disease, Type C (37)  ·  Metabolic Diseases (35)  ·  Wolman Disease (33)  ·  Dyslipidemias (32)

Broader conditions

Nutritional and Metabolic Diseases (1146)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1144)  ·  Lipid Metabolism Disorders (1121)  ·  Genetic Diseases, Inborn (1113)  ·  Metabolic Diseases (1113)  ·  Metabolism, Inborn Errors (1078)  ·  Lipidoses (626)  ·  Nervous System Diseases (619)  ·  Brain Diseases (573)  ·  Central Nervous System Diseases (572)  ·  Brain Diseases, Metabolic (566)  ·  Brain Diseases, Metabolic, Inborn (565)  ·  Lysosomal Storage Diseases, Nervous System (563)  ·  Sphingolipidoses (540)

Interventions

agalsidase beta (28)  ·  migalastat (28)  ·  agalsidase alfa (24)  ·  Ezetimibe (19)  ·  larazotide acetate (19)  ·  Atorvastatin (17)  ·  Glucosylceramidase (14)  ·  eliglustat (14)  ·  imiglucerase (14)  ·  Rosuvastatin Calcium (13)  ·  evolocumab (13)  ·  Blood Specimen Collection (12)  ·  ALN-PCS (11)  ·  miglustat (11)  ·  taliglucerase alfa (11)

Sponsors

Genzyme, a Sanofi Company (36)  ·  Shire (34)  ·  Amicus Therapeutics (29)  ·  Sanofi (24)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (18)  ·  Pfizer (18)  ·  CENTOGENE GmbH Rostock (16)  ·  Merck Sharp & Dohme LLC (16)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (15)  ·  Organon and Co (14)  ·  Novartis Pharmaceuticals (13)  ·  Alexion Pharmaceuticals, Inc. (12)  ·  IPCA Laboratories Ltd. (12)  ·  Par Pharmaceutical, Inc. (11)  ·  Regeneron Pharmaceuticals (11)

Countries

United States (497)  ·  Canada (152)  ·  United Kingdom (149)  ·  France (138)  ·  Germany (111)  ·  Italy (103)  ·  Spain (89)  ·  Netherlands (73)  ·  Australia (72)  ·  China (72)  ·  Brazil (62)  ·  Israel (59)  ·  Turkey (Türkiye) (57)  ·  Czechia (47)  ·  Belgium (46)

Top investigators

Forbes D Porter, M.D. (11)  ·  Peter Bauer, Prof. (8)  ·  Marina Cuchel, MD, PhD (7)  ·  Ozlem Goker-Alpan, MD (7)  ·  Joanne Kurtzberg, MD (5)  ·  Paul Orchard, MD (5)

Results publications

PMID 27657681, PMID 33990512, PMID 21586746, PMID 27578134, PMID 27839979, PMID 33332761, PMID 34617591, PMID 36279795, PMID 36520008, PMID 37624739, PMID 39847314, PMID 40525490, PMID 40587053, PMID 17407645, PMID 18473686, PMID 19029469, PMID 21401833, PMID 21613319, PMID 22087637, PMID 22500948, PMID 23176611, PMID 23348766, PMID 23860343, PMID 24014831, PMID 25614280, PMID 25795794, PMID 26053270, PMID 27053961, PMID 27509102, PMID 28476546, PMID 29688815, PMID 31889231, PMID 32609313, PMID 32994552, PMID 33482890, PMID 33980287, PMID 34349180, PMID 34387740, PMID 35788116, PMID 35916348, PMID 36196048, PMID 36461157, PMID 36481125, PMID 36721240, PMID 36739645, PMID 37171121, PMID 38101904, PMID 38776275, PMID 39271956, PMID 39745261

NIH funding

U54NS065768 (12), 2015 (9), 2017 (7), 2019 (7), 2005 (5), 2008 (5), 2016 (5), 2023 (5), 2014 (4), 2018 (4), 2025 (4), 2009 (3), K12CA120780 (1), P01HL030086 (1), P01HL059407 (1)